Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis

Simple item page
dc.contributor.authorSchneider, H.
dc.contributor.authorVan Rensburg, C.
dc.contributor.authorSchmidt, S.
dc.contributor.authorAboo, N.
dc.contributor.authorMakela, H.
dc.contributor.authorNaucler, E.
dc.contributor.authorHallerback, B.
dc.contributor.authorSvedberg, L-E.
dc.date.accessioned2011-05-15T16:16:15Z
dc.date.available2011-05-15T16:16:15Z
dc.date.issued2004
dc.description.abstractBackground/Aims: An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety after 1 and 4 weeks, and efficacy after 4 weeks' esomeprazole 40 mg once daily treatment, administered via an intravenous injection, intravenous infusion or orally, in patients with erosive esophagitis. Methods: In this double-blind, multi-centre study, patients with endoscopically confirmed erosive esophagitis (Los Angeles grade A-D) were randomized to receive 1 week's treatment of esomeprazole 40 mg once daily, via a 3-min injection, a 30-min infusion or orally, followed by 3 weeks of open treatment with oral esomeprazole 40 mg once daily. Safety variables were evaluated following 1 and 4 weeks' esomeprazole treatment. Healing rates at 4 weeks were estimated. Results: Intravenous and oral esomeprazole were equally well tolerated during the first week, and after 4 weeks' treatment. The 3 treatment groups showed similar levels of healing following 4 weeks' treatment with esomeprazole (injection + oral: 79.7%; infusion + oral: 80.2%; oral alone: 82.6%). Conclusions: Esomeprazole 40 mg administered via an intravenous injection, intravenous infusion or orally administered for 1 week, followed by 3 weeks of oral dosing, is well tolerated and provides effective healing of erosive esophagitis. Copyright © 2004 S. Karger AG.
dc.description.versionArticle
dc.identifier.citationDigestion
dc.identifier.citation70
dc.identifier.citation4
dc.identifier.issn00122823
dc.identifier.other10.1159/000083717
dc.identifier.urihttp://hdl.handle.net/10019.1/13698
dc.subjectesomeprazole
dc.subjectabdominal pain
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectcerebrovascular disease
dc.subjectclinical trial
dc.subjectconstipation
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdiarrhea
dc.subjectdizziness
dc.subjectdouble blind procedure
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug eruption
dc.subjectdrug formulation
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectdysentery
dc.subjectendoscope
dc.subjectfemale
dc.subjectflatulence
dc.subjectgastroenteritis
dc.subjectheadache
dc.subjecthealing
dc.subjectheart infarction
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectnausea
dc.subjectpriority journal
dc.subjectpruritus
dc.subjectrandomized controlled trial
dc.subjectreflux esophagitis
dc.subjectside effect
dc.subjectthorax pain
dc.subjectvertigo
dc.subjectvisual disorder
dc.subjectxerostomia
dc.subjectAdministration, Oral
dc.subjectAdult
dc.subjectAged
dc.subjectAnti-Ulcer Agents
dc.subjectDose-Response Relationship, Drug
dc.subjectEsophagitis
dc.subjectFemale
dc.subjectHumans
dc.subjectInfusions, Intravenous
dc.subjectInjections, Intravenous
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOmeprazole
dc.subjectTreatment Outcome
dc.titleEsomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications